# OnCo record vispacabtagene-regedleucel (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/vispacabtagene-regedleucel/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "vispacabtagene-regedleucel" ;
  schema:name "Vispacabtagene regedleucel"@en ;
  schema:alternateName "CB-010"@en, "vispa-cel"@en ;
  schema:description "Vispacabtagene regedleucel is an experimental allogeneic CAR-T cell therapy from Caribou Biosciences, in phase 1 trials for relapsed or refractory B cell non-Hodgkin lymphoma."@en ;
  schema:url <https://onco.cc/drugs/vispacabtagene-regedleucel/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.cariboubio.com/pipeline>, <https://www.cariboubio.com/pipeline>, <https://clinicaltrials.gov/api/v2/studies/NCT04637763>, <https://clinicaltrials.gov/search?intr=CB-010> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Allogeneic CAR-T cell therapy (CRISPR chRDNA genome-edited)" ;
  onco:cancers <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:targets <https://onco.cc/targets/cd19/> ;
  onco:companies <https://onco.cc/companies/caribou/> ;
  onco:trials <https://onco.cc/trials/nct04637763/> .